At a glance
ClinicalIndex Comparison RecordN/ACompleted· 10 enrolled
Drug / intervention
CapScan intestinal sampling devicedevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label Study to Evaluate the Use of the CapScan Intestinal Collection Device to Measure the Regional Metabolism of Sulfasalazine in the Digestive Tracts of Healthy Volunteers
In Brief
A clinical study evaluating CapScan intestinal sampling device for Healthy. Completed, enrolled 10 participants across 1 site.
Detailed Summary
Evaluation of the CapScan intestinal collection device in characterizing the metabolism of sulfasalazine in the digestive tracts of healthy volunteers.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
N/ACompletedFinished
2023202420252026
Enrollment StartSep 2022
Primary CompletionOct 2022
Study CompletionOct 2022
First PostedMar 2023
TodayJul 2026
First PostedMar 1, 2023
Enrollment StartSep 1, 2022
Primary CompletionOct 15, 2022
Study CompletionOct 30, 2022
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 3.3 years ago
Interventions
CapScan intestinal sampling devicedevice
CapScan is an intestinal collection device used to characterize the regional distribution of sulfasalazine, the metabolic breakdown products of sulfasalazine, and the gut microbiota in the digestive tracts of healthy volunteers.